INSIGHTS ON CLINICAL TRIAL DESIGN

  • Flexible, Global Delivery For Alzheimer's Patients

    Learn how MRN was able to take charge of overseeing clinical trial nurses and participants and work with Washington University to deliver clinical services to over 100 participants worldwide.

  • Exploring Global Clinical Trends In Cell And Gene Therapy

    Explore the exciting advancements in CNG treatment, such as innovative therapies, ongoing clinical trials, and their potential to positively influence patient outcomes.

  • Preparing For The Next Pandemic: Lessons Learned

    COVID-19 impacted how clinical trials are conducted and emphasized the need to stay ahead of emerging viruses and diseases. Explore insights on which measures and approaches will most likely continue to be implemented in the future.

  • There Is More To CDMS Than EDC

    EDC alone cannot solve the data challenges posed by hybrid digital trials. Discover how this role can be taken on by also aggregating, cleaning, and providing user-based access to all trial data.

CLINICAL TRIAL DESIGN SOLUTIONS

  • Our expert central nervous system (CNS) teams have extensive experience and strong knowledge of the challenges expected when implementing and mitigating CNS clinical trials.

  • Leveraging a partner with expertise and integrated, end-to-end solutions can help overcome obstacles to increase patient access and ensure the safe distribution of your advanced therapy product.

  • Many biotechnology companies come to Australia to conduct early phase clinical trials and take advantage of straightforward regulatory streams and of the lucrative 43.5% R&D cash refund scheme. Biotechnology companies then often look at locations in Asia, such as South Korea, Thailand and China to tap into their huge treatment-naïve patient populations for their later phase clinical research.

  • As the healthcare industry continues to deepen its focus on virtual trials and patient-centricity, the popularity of Direct-to-Patient (DtP) services in the clinical trial setting has grown significantly. Rave RTSM DtP (Randomization and Trial Supply Management Direct to Patient) brings investigational medicinal products (IMP) directly to a patient’s home, bypassing the need for the patient to travel directly to a site.

  • Read how Biorasi's speed and agility make all the difference in overcoming unique obstacles to rare disease clinical trials.